Biolink Life Sciences, Inc.

Other

Nutrition 21, Inc.

Bonafide Health, LLC

Barbeau Pharma, Inc.

Bioniche Teoranta

Deanna J Nelson

James R Komorowski

Navdeep Balkrishna Malkar

Walter C Holberg, Iii

Donald L Barbeau

Brian J Mosley

Walter Charles Holberg, Iii

Compounds, compositions and methods of making and using for enhancing the quality and benefit of sleep and/or wakefulness in a subject in need thereof.

Method and composition for enhancing the quality and benefits of sleep

The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Magnesium biotinate compositions and methods of use

The present invention relates to a liquid concentrate of calcium propionate and a magnesium salt, optionally with sweetener, taste-masking agent, flavoring, and thickening agent. Also provided is a method for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of a subject by administering to the subject a liquid concentrate of at least calcium salt and magnesium salt.

Liquid concentrates of calcium and magnesium

The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

Magnesium picolinate compositions and methods of use

The present application relates to strontium L-lactate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable strontium to mammals and treating or preventing symptoms of bone and/or cartilage disorders.

Pharmaceutical quality strontium L-lactate

The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.

Phosphorus binder composition for treatment of hyperphosphatemia

The present invention relates to oral nutritional and therapeutic products which are useful for providing vitamins and minerals required for bone health. The present invention is an oral nutritional and therapeutic composition of calcium succinate, magnesium R-(+)-alpha-lipoate, and Vitamin D for use in the maintenance of bone health, the optimization of bone growth, reducing the risk of bone fracture, and the prevention and treatment of osteoporosis. The pharmaceutical products and methods of the present invention are particularly useful in building bone mass, quality, and density during growth, maintaining bone mass, quality, and density over time, reducing bone fracture risk, and treating osteoporosis in men and women.

Combined calcium, magnesium and vitamin D supplements

The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.

Stable, water-insoluble R-(+)-&#x3b1;-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities

New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications.

Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof

The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.

Phosphorus binder for treatment of renal disease

The present invention relates to stable and highly purified stable hydralazine hydrochloride compositions and stable hydralazine-containing pharmaceutical compositions. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration is described comprising a therapeutically effective dose of hydralazine hydrochloride in a pharmaceutically acceptable carrier or diluent wherein the hydralazine hydrochloride is essentially free of phthalazines, hydrazine and metal ions. In addition, a stable sterile aqueous pharmaceutical composition comprising hydralazine hydrochloride in a pharmaceutically acceptable salt or diluent is described that is colorless and has no visible particulate matter.

Growing community of inventors

Raleigh, NC, United States of America

Deanna J Nelson